Cardiology

An analysis of data from patients admitted to emergency departments from 7 hospitals in Sweden provide insight into the potential of blood glucose at admission for use as a biomarker to predict all-cause mortality and cardiovascular risk in patients without a history of diabetes.

An analysis of self-reported dietary information from UK Biobank participants is providing insight into the effects of reducing added salt to foods on cardiovascular disease risk among adults without a history cardiovascular disease.

This case report features a patient in their mid-70s with a history of hypertension is brought in with chest pain radiating to both shoulders along with nausea and mild shortness of breath. Check out the full case report and determine the correct diagnosis!

An analysis of more than 800k women in Canada provides insight into the apparent increase in risk of incident cardiovascular disease associated with co-occurrence of gestational diabetes and gestational hypertensive disorders in pregnant women.

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.

A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.

An analysis of data from 2010-2019 collected from 10 countries suggests influenza activity is responsible for 299k ischemic heart disease deaths per year on a global level.

Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

Announced in a statement on November 17, the US FDA issued letters to 7 companies related to unsupported claims of supplements being able to cure, treat, mitigate or prevent cardiovascular disease or related conditions, such as atherosclerosis, stroke or heart failure, in violation of the Federal Food, Drug, and Cosmetic Act.

An analysis of more than 8 million live singleton births in Nordic countries is providing insight into the impact of maternal preeclampsia on risk of ischemic heart disease and stroke in offspring during childhood and young adulthood.

Data from the ATLAS trial indicate use of a subcutaneous ICD was associated with a 92% reduction in lead-related complications compared to TV-ICD without compromising the effectiveness of shocks, but investigators express caution over an increased incidence of inappropriate shocks with the S-ICD.

Our editorial team has compiled a list of the top data and news from the American Heart Association 2022 Scientific Sessions, with a focus on heart failure, hypertension, and lipid management.

An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.

Our latest case report from Brady Pregerson, MD, features a patient in their mid-60s with a history of hypertension and hyperlipidemia who is brought in by medics with severe bradycardia and diaphoresis after a near syncopal episode. Can you determine the correct diagnosis?

Aruna Pradhan, MD, MPH, joins The Heart Team at AHA 2022 to discuss the design, results, and her interpretation of the PROMINENT trial for practicing clinicians as well as how she interprets use of triglyceride-lowering agents in the wake of PROMINENT and RESPECT-EPA results.

At AHA 2022, Dr. Ray discusses the findings from the phase II open-label extension trial and highlights other important trial data for lipidologists.

A pair of studies leveraging NIS data detail the risk of cardiovascular complications during delivery admissions among pregnant persons with a history of systemic lupus erythematosus or use of assisted reproductive technologies relative to their counterparts who did not.

A deep dive into exciting late-breaking trial data at AHA 2022, differences in chest pain guidelines, and bringing patient voice into clinical research.

Ridker joins to discuss some of his recent work, provide a deep dive into use of inflammatory biomarkers for identifying patients with residual inflammatory risk, provide perspective on use of MACE compared with all-cause mortality in cardiovascular clinical trials, and discuss the optimized uptake of SGLT2 inhibitors in care.

A Q&A with Dr. Bonaca highlights new data on rivaroxaban for PAD and the late-breaking science at AHA 2022.

Data from a pair of presentations at AHA 2022 Scientific Sessions provide clinicians with insight into the effects of surgical vs endovascular procedures for improving prognosis and reducing amputation in patients with peripheral artery disease.

In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.

The trial achieved its primary efficacy endpoint of terminating PSVT with self-administered etripamil, using symptom-based optional repeat dosing.

Results of the CTS-AMI study presented at AHA 22 suggests tongxiluo, which is an herbal medicine compound used in China, could reduce risk of cardiac events and mortality following a heart attack.

Patients with early VA-ECMO use saw comparable outcomes to those who initially received conservative therapy for hemodynamic stabilization.

Education and place of birth contribute the most to the racial and ethnic differences observed in mean CVH score.

The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.

A single intravenous dose of NTLA-2001 significantly reduced abnormal levels of transthyretin in patients with ATTR amyloid cardiomyopathy, reports new data from AHA 2022.